Immunovant (IMVT) Common Equity (2018 - 2026)
Immunovant's (IMVT) quarterly Common Equity came in at $852.6 million in Q1 2026, up 20.52% YoY from $707.4 million in Q1 2025, and down 13.54% on a QoQ basis from $986.1 million in Q4 2025.
Immunovant (IMVT) Common Equity (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of Common Equity data on file, last reported at $852.6 million in Q1 2026.
- Quarterly Common Equity rose 20.52% year-over-year to $852.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $852.6 million (up 20.52% YoY) and the FY2026 annual result came in at $852.6 million, up 20.52% from the prior year.
- Common Equity slipped to $852.6 million in Q1 2026, from $986.1 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $986.1 million in Q4 2025 to a low of $251.8 million in Q3 2023.
- A 5-year average of $526.4 million and a median of $469.8 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity plunged 48.09% — and 2025, when it surged 179.66%.
- Tracing IMVT's Common Equity over 5 years: stood at $414.7 million in 2022, then surged by 63.82% to $679.3 million in 2023, then sank by 48.09% to $352.6 million in 2024, then surged by 179.66% to $986.1 million in 2025, then dropped by 13.54% to $852.6 million in 2026.
- The last three Common Equity figures came in at $852.6 million (Q1 2026), $986.1 million (Q4 2025), and $519.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | 735.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 735.39 Mn |
| Mar 31, 2026 | 852.59 Mn |
| Dec 31, 2025 | 986.14 Mn |
| Sep 30, 2025 | 519.71 Mn |
| Jun 30, 2025 | 608.54 Mn |
| Mar 31, 2025 | 707.45 Mn |
| Dec 31, 2024 | 352.62 Mn |
| Sep 30, 2024 | 449.05 Mn |
| Jun 30, 2024 | 544.66 Mn |
| Mar 31, 2024 | 617.76 Mn |
| Dec 31, 2023 | 679.34 Mn |
| Sep 30, 2023 | 251.81 Mn |
| Jun 30, 2023 | 299.87 Mn |
| Mar 31, 2023 | 362.49 Mn |
| Dec 31, 2022 | 414.68 Mn |
| Sep 30, 2022 | 395.75 Mn |
| Jun 30, 2022 | 436.49 Mn |
| Mar 31, 2022 | 469.83 Mn |
| Dec 31, 2021 | 505.15 Mn |
| Sep 30, 2021 | 536.40 Mn |